Inherited thrombophilia due to factor V Leiden mutation

Molecular Diagnosis

Volumn 3, Issue 1, 1998, Pages 55-62

  Mattson, Joan C ^a   Crisan, Domnita ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Activated protein C resistance; Hypercoagulable states; Thromboembolic disease

Indexed keywords

BLOOD CLOTTING FACTOR 5; PROTEIN C;

ANTICOAGULATION; BLOOD CLOTTING DISORDER; ETHNIC DIFFERENCE; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN CELL; HUMAN TISSUE; POINT MUTATION; PROTEIN ANALYSIS; REVIEW; RISK FACTOR; THROMBOPHILIA; THROMBOSIS;

EID: 0031807088     PISSN: 10848592     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1084-8592(98)80027-1     Document Type: Review

References (59)

1. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study
2. Deep-Vein Thrombosis
3. Deficiencies of Coagulation-Inhibiting and Fibrinolytic Proteins in Outpatients with Deep-Vein Thrombosis
4. The protein C anticoagulant system: Inherited defects as basis for venous thrombosis
5. Blood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders
6. The physiology and biochemistry of factor
7. The protein C anticoagulant pathway
8. Regulation of blood coagulation by the protein C system
9. Mutation in blood coagulation factor V associated with resistance to activated protein C
10. The mechanism of inactivation of human factor V and human factor Va by activated protein C
11. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa
12. Regulation of activated protein C by a new protein. A possible function for bovine protein S
13. Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C
14. Factor V enhances the cofactor function of protein S in the APC-mediated inactivation of factor VIII: influence of the factor VR506Q mutation
15. Familial thrombophilia associated with resistance to activated protein C is due to a deficiency of a novel protein C cofactor.
16. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C
17. Twenty novel families with thrombophilia and inherited resistance to activated protein C
18. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V
19. Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasmas from healthy individuals
20. Modified test for activated protein C resistance
21. Use of a generally applicable tissue factor--dependent factor V assay to detect activated protein C-resistant factor Va in patients receiving warfarin and in patients with a lupus anticoagulant
22. Specificity of an assay based on a factor V-depleted plasma in patients carrying the Arg 506 Gin mutation
23. Screening for the FV:Q506 mutation--evaluation of thirteen plasma-based methods for their diagnostic efficacy in comparison with DNA analysis
24. Hoagland L.E., Triplett D.A., Peng F., Barna L.APC-resistance as measured by a textarin time assay: comparison to the APTT-based method.Thrombosis Research 83(5),1996,pp:363-373.
25. Modified APC resistance assay for patients on oral anticoagulants
26. The modified APC resistance assay in the presence of factor V deficient plasma can be used in patients without oral anticoagulant
27. Resistance to activated protein C, the Arg 506 to Gln mutation in the factor V gene, and venous thrombosis
28. A rapid screening method for the factor V Arg506???Gln mutation
29. Evaluation of a tissue factor dependent factor V assay to detect factor V Leiden: demonstration of high sensitivity and specificity for a generally applicable assay for activated protein C resistance
30. Genetic detection of factor V Leiden: the question of specificity
31. Resistance to Activated Protein C as a Basis for Venous Thrombosis
32. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study
33. Molecular detection of factor V Leiden in patients presenting with thrombotic episodes
34. Anticoagulant protein C pathway defective in majority of thrombophilic patients
35. Variability of Thrombosis among Homozygous Siblings with Resistance to Activated Protein C Due to an Arg-to-Gln Mutation in the Gene for Factor V
36. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C
37. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation
38. Public health economic evaluation of screening for APC resistance (Leiden mutation) in new oral contraceptive users
39. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families
40. Homozygous APC-resistance combined with inherited type I protein S deficiency in a young boy with severe thrombotic disease
41. PULMONARY EMBOLISM AND PREMATURE LABOR IN A PATIENT WITH BOTH FACTOR V LEIDEN MUTATION AND METHYLENETETRAHYDROFOLATE REDUCTASE GENE C677T MUTATION
42. Inborn Errors of Metabolism Causing Homocysteinemia and Related Vascular Involvement
43. Coexistence of Hereditary Homocystinuria and Factor V Leiden — Effect on Thrombosis
44. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
45. Factor V Leiden and other coagulation factor mutations affecting thrombotic risk
46. No association of APC resistance with myocardial infarction
47. Ischemic Stroke in Young Patients With Activated Protein C Resistance : A Report of Three Cases Belonging to Three Different Kindreds
48. Mutation in the Gene Coding for Coagulation Factor V and the Risk of Myocardial Infarction, Stroke, and Venous Thrombosis in Apparently Healthy Men
49. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening
50. Detection of the factor V Leiden mutation in a nonselected black population
51. Prevalence of the factor V mutation in the Egyptian population
52. World distribution of factor V Leiden
53. Current status and problems of venous thrombosis in Japan
54. APCresistance and Mnl I genotype (Gln 506) of coagulation factor V are rare in Japanese population
55. Study of the relation between the FV Leiden nutation and Chinese APC resistance
56. APC resistance and factor V mutation might be absent in the Korean population
57. Evidence for a single origin of factor V Leiden
58. Activated protein C resistance caused by a common factor V mutation has a single origin
59. A single genetic origin for the common Caucasian factor V mutation predisposing to thrombosis.